Question for written answer - European Parliament

?Question for written answer E-004584/2020to the CommissionRule 138Petros Kokkalis (GUE/NGL)Subject:COVID-19 vaccineThe Commission President has today announced the conclusion of an agreement with AstraZeneca for the purchase of 300 million doses of vaccine, with an option to purchase 100 million more. Clinical trials have now reached phase III, corresponding to 2/3 of the EU population initially, rising to a total of 90%. The Commission will be working together with the Member States and the European Medicines Agency to introduce a fast-track procedure for the approval of successful vaccines, making full use of the leeway offered by existing framework provisions, in order to speed up their deployment.In view of this:1.Can the Commission say what measures it will take to uphold quality and safety standards and ensure affordability at every stage of the fast-track procedure to combat the COVID-19 virus?2.Will such flexibility be limited to companies that have already concluded an agreement with the EU or will it be used in a bid to find the best vaccine?3.How will the Commission guarantee fair distribution based on population figures, as announced, in view of the revelation by the Greek minister responsible that only 3 million doses have been earmarked for Greece for a seven-month period, corresponding to less than one-third of its population? ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download